MGM Resorts International (MGM)
MGM Resorts International, formerly known as MGM MIRAGE, is a global hospitality company, operating a portfolio of destination resort brands, including Bellagio, MGM Grand, Mandalay Bay and The Mirage. The Companys resorts offer gaming, hotel, dining, entertainment, retail, and other resort amenities. It owns and operates properties located in Nevada, Mississippi and Michigan, and has investments in some properties in Nevada, Illinois and Macau. Through its hospitality management subsidiary, the Company holds a growing number of development and management agreements for casino and non-casino resort projects around the world. MGM Resorts International is based in Las Vegas, Nevada.
MGM Resorts International (MGM)‘s Financial Overview
MGM Resorts International (MGM) declined -2.18% yesterday to close its trading session at $34.1. The company has 1 year Price Target of $40.29. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 6.56 Million shares yesterday. The firm shows the market capitalization of $20.04 Billion.
The firm is trading with SMA20 of -3.13 Percent, SMA50 of SMA50 Percent and SMA200 of 2.97 percent. MGM Resorts International has P/S value of 1.86 while its P/B value stands at 2.54. Similarly, the company has Return on Assets of 6.7 percent, Return on Equity of 29 percent and Return on Investment of 7.1 Percent. The company shows Gross Margin and Operating Margin of 42.8 percent and 15.9 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 17 analysts offering 12-month price forecasts for MGM Resorts International have a median target of 39.00, with a high estimate of 44.00 and a low estimate of 36.00. The median estimate represents a +14.37% increase from the last price of 34.10.
Endo International plc (ENDP)
Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.
Endo International plc (ENDP)‘s Financial Outlook
The 19 analysts offering 12-month price forecasts for Endo International PLC have a median target of 10.00, with a high estimate of 17.00 and a low estimate of 6.00. The median estimate represents a +71.23% increase from the last price of 5.84.
According to Zacks Investment Research, Endo International plc has a Consensus Recommendation of 2.52. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged0.86% and closed its last trading session at $5.84. The company has the market capitalization of $1.35 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 6.48 Million shares. The company has a total of 230.55 Million shares outstanding.
The company has YTD performance of -24.65 percent. Beta for Endo International plc stands at 0.35 while its ATR (average true range) is 0.35. The company has Weekly Volatility of 4.83%% and Monthly Volatility of 5.71%.
Endo International plc has distance from 20-day Simple Moving Average (SMA20) of -12.02%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -29.71%.
The Company currently has ROA (Return on Assets) of -16.6 percent, Return on Equity (ROE) of -191.7 Percent and Return on Investment (ROI) of -9.1% with Gross margin of 35.8 percent and Operating & Profit margin of -29.2% and -58.7% respectively.